Association between VEGF gene promoter polymorphisms and bladder cancer: An updated meta-analysis

Chen, Chih Heng; Ho, Chen Hsun; Huang, Steven Kuan-Hua; Shen, Cheng; Wu, Chia Chang; Wang, Yuan Hung

doi:10.1016/j.cyto.2020.155112

Cited by 6 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aside from that, no statistically significant correlation was revealed between VEGFA polymorphisms and BC parameters; these results confirm previously reported data highlighting the absence of correlations between −460 T/C and −2549 I/D polymorphisms and BC staging, grading, and tumor progression [ 6 , 19 ]. However, a recent meta-analysis showed significant correlations between the −2578 C/A polymorphism and histological grade and tumor stage in BC [ 16 ].…”

Section: Discussionsupporting

confidence: 89%

“…Currently, it is widely accepted that several polymorphisms in the VEGFA promoter are reported to affect the gene expression [ 6 ]. Thus, we evaluated the genetic association between VEGFA SNPs (−460 T/C, −2578 C/A, and −2549 I/D) and the gene expression profile.…”

Section: Discussionmentioning

confidence: 99%

“…In solid tumors, including BC, hypoxia was reported to correlate with poor prognoses and low survival rates in cancer patients [ 5 ]. The vascular endothelial growth factor (VEGF) is the major regulator of angiogenesis, which contributes to key aspects in the tumor microenvironment, including the function of cancer stem cells and tumor initiation [ 6 ]. VEGFA is identified by the ability to stimulate the vascular endothelial cell proliferation and to increase the vascular permeability.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer

et al. 2023

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) are the most important tissue factors involved in tumor growth and angiogenesis. The aim of this study was to evaluate the promoter mutational status of VEGFA and the expression levels of VEGFA, VEGFR1, and VEGFR2 in bladder cancer (BC) tissues and to correlate the results with the clinical–pathological parameters of BC patients. A total of 70 BC patients were recruited at the Urology Department of the Mohammed V Military Training Hospital in Rabat, Morocco. Sanger sequencing was performed to investigate the mutational status of VEGFA, and RT-QPCR was used to evaluate the expression levels of VEGFA, VEGFR1, and VEGFR2. Sequencing of the VEGFA gene promoter revealed the presence of −460T/C, −2578C/A, and −2549I/D polymorphisms, and statistical analyses showed a significant correlation between −460T/C SNP and smoking (p = 0.02). VEGFA and VEGFR2 expressions were significantly up-regulated in patients with NMIBC (p = 0.003) and MIBC (p = 0.03), respectively. Kaplan–Meier analyses showed that patients with high VEGFA expression had significantly longer disease-free survival (p = 0.014) and overall survival (p = 0.009). This study was very informative, showing the implication of VEGF alterations in BC, suggesting that VEGFA and VEGFR2 expressions could be promising biomarkers for the better management of BC.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, precise regulation of VEGFA expression may reduce the occurrence of cardiovascular diseases, including CHD. [ 27 ] This further confirms the characteristics of GLXBGZD to treat CHD through multiple components and targets.…”

Section: Discussionsupporting

confidence: 65%

Study on the mechanism of Gualou Xiebai Guizhi decoction (GLXBGZD) in the treatment of coronary heart disease based on network pharmacology

Chen¹,

Wang

Pang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: This study aims to analyze the mechanism of Gualou Xiebai Guizhi decoction (GLXBGZD) in treating coronary heart disease (CHD) utilizing network pharmacology. Methods: The GLXBGZD effective components were searched on the pharmacological database platform of the Traditional Chinese Medicine Systems Pharmacol, and its potential target was predicted. The Online Mendelian Inheritance obtained CHD disease target in Man and GeneCards database. The Venn map of the intersection target for GLXBGZD and CHD was constructed by using Venn online website. The “drug-component-target-disease” network map was constructed by Cytoscape 3.7.2 software. The DAVID online platform was used to analyze the function of Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) at the intersection of targets of drugs and diseases. Results: A total of 27 articles were searched for GLXBGZD, including 111 potential targets, 5521 disease targets, 100 drug and disease intersection targets. The core target network map shows that Interleukin (IL)-6, TNF, vascular endothelial growth factor (VEGFA), TP53, EGF, JUN, MAPK1, Catalase (CAT), and prostaglandin-endoperoxide synthase 2 (PTGS2) may be the key targets in CHD therapy. GO functional enrichment analysis revealed that the biological functions of GLXBGZD involved biological processes such as response to drugs, positive regulation of nitric oxide biosynthesis process, and response to hypoxia. KEGG pathway enrichment analysis showed that GLXBGZD might participate in CHD treatment through Hypoxia-inducible factor-1 (HIF-1), Tumor necrosis factor (TNF), PhosphoInositide-3 Kinase--Threonine protein kinase (PI3K-Akt), and the calcium signal pathway. Conclusions: This study reveals that the GLXBGZD mechanism in CHD treatment has the characteristics of multi-components, multi-targets, and multi-pathways, which provides a theoretical basis for its clinical application and subsequent experimental verification.

show abstract

“…Feng et al [ 10 ] showed, in a meta-analysis, that the VEGF +936C>T gene polymorphism is significantly associated with an increased risk of developing malignant digestive system tumors. Chen et al [ 11 ] reported a modest significance of VEGF -2578C/A polymorphism as a risk factor for bladder cancer. No significant associations of VEGF +936C/T, -460C/T, and -2578C/A gene polymorphisms with lung cancer have been reported by Yang et al [ 12 ] in a meta-analysis conducted on 13 independent case–control studies, with a total of 4477 patients with lung cancer and 4346 healthy controls.…”

Section: Introductionmentioning

confidence: 99%

Genetic Polymorphisms of Vascular Endothelial Growth Factor in Neonatal Pathologies: A Systematic Search and Narrative Synthesis of the Literature

et al. 2023

View full text Add to dashboard Cite

(1) Background: Vascular endothelial growth factor (VEGF) is essential in vasculo- and angiogenesis due to its role in endothelial cell proliferation and migration. As a vascular proliferative factor, VEGF is one of the hallmarks of cancer and, in adult populations, the relationship between genetic polymorphism and neoplasm was widely investigated. For the neonatal population, only a few studies attempted to uncover the link between the genetic polymorphism of VEGF and neonatal pathology, especially related to late-onset complications. Our objective is to evaluate the literature surrounding VEGF genetic polymorphisms and the morbidity of the neonatal period. (2) Methods: A systematic search was initially conducted in December 2022. The PubMed platform was used to explore MEDLINE (1946 to 2022) and PubMed Central (2000 to 2022) by applying the search string ((VEGF polymorphism*) and newborn*). (3) Results: The PubMed search yielded 62 documents. A narrative synthesis of the findings was undertaken considering our predetermined subheadings (infants with low birth weight or preterm birth, heart pathologies, lung diseases, eye conditions, cerebral pathologies, and digestive pathologies). (4) Conclusion: The VEGF polymorphisms seem to be associated with neonatal pathology. The involvement of VEGF and VEGF polymorphism has been demonstrated for retinopathy of prematurity.

show abstract

Association between VEGF gene promoter polymorphisms and bladder cancer: An updated meta-analysis

Cited by 6 publications

References 28 publications

The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer

The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer

Study on the mechanism of Gualou Xiebai Guizhi decoction (GLXBGZD) in the treatment of coronary heart disease based on network pharmacology

Genetic Polymorphisms of Vascular Endothelial Growth Factor in Neonatal Pathologies: A Systematic Search and Narrative Synthesis of the Literature

Contact Info

Product

Resources

About